SUMMARY -New data gathered from large clinical trials indicate that nonobstructive coronary artery disease (non-CAD) is a clinical entity that should not be ignored. It is estimated that 50% of female population undergoing coronarography are diagnosed with non-CAD. Th ere is also an increase in the prevalence of non-CAD in both genders, which is probably due to gradual expanding of clinical indications for angiography in patients with angina. Furthermore, considering the increased mortality risk established recently, a prognosis of non-CAD is not benign as previously thought. However, the concept and defi nition of non-CAD remains elusive causing diffi culties in diagnosis and treatment. One of the major shortcomings is the exclusion-based diagnosis of non-CAD. Furthermore, treatment of non-CAD still presents a great challenge and optimal therapy is yet to be determined. Th ere are two major hypotheses explaining the pathophysiological mechanisms of non-CAD, i.e. ischemic hypothesis based on abnormal microvascular dysfunction and non-ischemic one based on altered pain perception. Th is review encompasses a broader spectrum of pathophysiological mechanisms of non-CAD, and proposes a new way of classifi cation based on the major disorder involved: type I (ischemic mechanisms) and type II (non-ischemic mechanisms), depending on which mechanism predominates. Hopefully, this would provide new insights in the understanding of this disorder, thus leading to accurate and early diagnosis and successful treatment, especially considering the increased mortality risk in these patients.
Introduction
Th e concept of coronary syndrome X (CSX) was introduced in clinical practice in 1973 by Kemp et al. to describe patients with angina during physical exercise and normal coronarography [1] [2] [3] . Over time, this term has encompassed a broader spectrum of patients including those with angina regardless of the cause and absence of signifi cant changes on coronary vessels 2 . Patients with other cardiac pathology such as cardiomyopathies, left ventricular hypertrophy or signifi cant valvular disease are usually, although not always, excluded from this defi nition 4 . Many authors recommend associating this syndrome with angina and microvascular dysfunction 5 . On the other hand, some authors suggest exclusion of certain diseases, such as hypertension or diabetes, which can lead to microvascular dysfunction 6 .
Classic defi nition of CSX is: angina during physical exertion, signifi cant changes of ST segment during exercise test, and angiographically smooth coronary arteries in the absence of other cardiac or systemic diseases (e.g., hypertension and diabetes), which can lead to vascular dysfunction 6 . Th is defi nition is presently inappropriate for research and clinical purpose, the main objection being the impossibility of including all patients with microvascular dysfunction 5 . Hence, new, more appropriate defi nitions have recently been introduced by scientifi c community.
Lanza has proposed that CSX consists of chest pain predominantly during physical exertion, established ischemia or diminished coronary reserve, using noninvasive provocation tests, normal (or almost normal) coronary arteries at angiography with stenosis less than <20%, and exclusion of other specifi c diseases such as Prinzmetal's angina, cardiomyopathies and valvular heart disease 5 . Accordingly, the CSX now includes not only conditions with diminished coronary reserve that can be established with modern diagnostic procedures of ergometry, stress induced myocardial scintigraphy, pharmacological stress tests or ECG Holter monitor test, but also other diseases such as hypertension or diabetes, which are common causes of microvascular dysfunction 7 . Owing to the new understandings, Cannon and Epstein introduced a new concept of microvascular angina in 1985 8 . Th is concept defi nes CSX as chest pain with normal coronary angiography associated with enhanced sensitivity of microcirculation to vasoconstrictive infl uences or abnormal vasodilatory response due to endothelial dysfunction. Th e level of endothelin (vasoconstrictor) in plasma of these patients is signifi cantly increased 9 . Th is was an attempt to unite pathophysiology of the clinical condition, accentuate signifi cant role of endothelial dysfunction, and achieve a more homogeneous group of patients. However, this approach is not fully satisfying since it becomes more obvious that endothelial dysfunction is only part of the pathophysiological cascade.
In 2011, Kothawade et al. suggested a new term of microvascular coronary dysfunction (MCD) 10 . Th e CSX is defi ned as diminished coronary reserve and/or coronary endothelial dysfunction, and is clinically presented with a triad of symptoms: persistent chest pain, nonobstructive coronary disease (coronary artery stenosis <50% on coronarography), and ischemia established with noninvasive methods 10 . Th e gold standard for MCD diagnosis is invasive coronary reactivity testing (CRT) 10 . Regardless of defi nition and terminology, it is necessary to emphasize that obstructive coronary disease (CAD) indicates stenosis of coronary vessel ≥50% on coronarography, while nonobstructive coronary disease (non-CAD) indicates stenosis of coronary artery <50% 11 . Th at criterion is common to all defi nitions and understandings of this complex clinical syndrome.
However, there are still some diff erences in understanding non-CAD that cause discrepancies in results and observations. Th erefore, new defi nitions should be considered to enable unique and accurate defi ning of this clinical entity with all its diversities.
Nonobstructive Coronary Artery Disease -Pathophysiological Mechanisms
Th ere are two major hypotheses explaining the pathophysiological mechanisms of non-CAD, i.e. ischemic and non-ischemic hypotheses 12 . Ischemic theory is based on abnormal microvascular dysfunction, whereas non-ischemic theory is grounded on altered pain perception [12] [13] [14] [15] [16] .
Ischemic hypothesis
Since the time when CSX was recognized as a specifi c clinical entity, it was assumed that chest pain was caused by dysfunction of small coronary arteries (<500 μm), not seen during coronarography, hence naming the whole syndrome microvascular angina 8 . Myocardial ischemia in these patients can be established by ST segment changes at rest or exertion and by perfusion redistribution on scintigraphy 13 . Moreover, there is some metabolic evidence for ischemia during exercise, e.g., increased lactate production, decreased oxygen saturation in coronary sinus, decreased pH and increased phosphate consumption on nuclear magnetic resonance (NMR), which can be confi rmed in 20% of patients 15 . However, not all studies managed to demonstrate the presence of ischemia since disturbance of regional contractility was not confi rmed by echocardiography 16 . In 1991, Maseri et al. 14 tried to explain this contradictory observation with the following hypothesis. Microvascular dysfunction encompasses small prearterio-lar vessels (100-500 μm), while their inadequate vasodilative response during exercise or pharmacological stress tests leads to localized ischemia surrounded by areas with functioning arteriolar vessels. Th is induces compensatory response by increasing contractility, thus preventing diagnosis of regional or global contractility disturbance by echocardiography.
Coronary fl ow is regulated by endothelial dependent and non-endothelial dependent factors, which regulate macro-and microvascular blood vessel tone. Endothelial dependent factors regulate coronary reserve modulating vasomotor tone by releasing vasoactive factors. Th e most important vasodilator is nitric oxide (NO), a factor released by endothelial cells. Non-endothelial dependent factors encompass aortal pressure, myocardial contractility output, neurohumoral mechanisms and myocardial metabolism 17 . Endothelial dysfunction leads to vasodilatory imbalance between NO and vasoconstrictor endothelin-1 and reduced release of anti-infl ammatory and antithrombotic factors 17 . Since microvascular dysfunction cannot be established by classic coronary angiography (coronarography) and there are no other available methods at present for visualizing vasculature smaller than 500 μm, other diagnostic methods are needed to indirectly demonstrate microvascular dysfunction. Th ese tests can be invasive (thermodilution and invasive evaluation of coronary fl ow) or noninvasive (myocardial scintigraphy-radionuclide perfusion, positron emission tomography (PET), NMR) 17 . Th e gold standard in the diagnosis of vascular dysfunction is invasive evaluation of coronary fl ow reserve. Coronary fl ow reserve is an increase in blood fl ow in response to metabolic or pharmacological stimuli 19 . Diminished coronary reserve is an indicator of possible ischemia, which could be provoked by increase in myocardial oxygen demand. Results of the above mentioned test indicate that microvascular dysfunction is a plausible cause of CSX. Novel studies using magnetic resonance (MR) confi rm decreased subendocardial perfusion in patients with CSX compared to healthy control group 19 . PET demonstrated diminished coronary reserve in 50% to 60% of female patients with non-CAD, and MRI in 25% of the same population 19 . However, the prevalence of ischemia is probably underestimated with MR considering the limited ability to induce stress or exertion during MR 20 .
Obviously, microvascular dysfunction is a very important mechanism in the development of non-CAD. Primary disorder in microvascular dysfunction is altered (decreased) vasodilative response to adequate stimuli, but in a specifi c group of patients enhanced vasoconstrictory response can be present 21 . Decreased endothelial dependent vasodilation (endothelial dysfunction) is diagnosed with provocation tests using acetylcholine or with direct electrostimulation of the right atrium, while non-endothelial dependent dysfunction can be established by adenosine, pyridamole or papaverine provocation tests 21, 22 . Abnormal vasoconstriction can be confi rmed by provocation with ergonovine, cold, hyperventilation, handshake test and acetylcholine 23 . After performing one of these provocation tests, diminished coronary reserve should be diagnosed with one of the previously mentioned methods (indirectly invasive -coronary fl ow reserve test or noninvasive tests -PET, MR).
Based on the resu lts of our recently published research 24 , we propose a new mechanism that could be added to endothelial independent mechanisms within the ischemic hypothesis on the development of non-CAD. Alongside the known endothelial independent pathophysiological mechanisms such as aortic pressure, myocardial contractility, myocardial metabolism and neurohumoral factors 25 , another possible contributor would be the type of coronary supply, specifi cally the left type of dominance (particularly in women), and absence of mixed type in men 24 .
Non-ischemic hypothesis
Non-ischemic hypothesis explains the CSX phenomenon and non-CAD because of altered pain perception 25 . Previous studies demonstrated that patients with angina and normal coronary arteries had enhanced pain perception to heat and electrical stimuli 26 . Th ere is evidence supporting the absence of habituation to frequent pain stimuli in these patients (habitual theory) 27 . Furthermore, it is well known that estrogen has analgesic properties, which are mediated through opioid system, thus explaining the presence of chest pain in postmenopausal women with normal coronarography. It is possible that the lack of estrogen in females participates in altered chest pain perception 28 . In 1988, Shapiro et al. demonstrated that intracardial stimulation by infusion of saline to the right atri-um induced chest pain in patients with angina and normal coronary arteries 29 . It was the fi rst paper published that explained this phenomenon using altered pain perception. Although results of previous studies indicated generally diminished tolerance to all pain stimuli in these patients, the study by Iannetti et al. denied such notion 30 . Earlier studies were poorly controlled and badly designed, whereas new studies with laser pain stimuli on the skin surface established unaltered general pain perception. In addition, local electrostimulation of the right ventricle with higher frequencies demonstrated altered pain perception in the heart 30 . Rosen et al. demonstrated that activation of the right frontal insula of the brain cortex in patients with CSX and ST changed during dobutamine stress test, suggesting cortical origin of this disorder 31 . Aff erent (sympathetic) and eff erent (nociceptive) fi bers can be aff ected as well 31 . Enrolment of the sympathetic heart system (aff erent component) can be clinically diagnosed by metaiodobenzylguanidine (MIBG) scintigraphy. In patients with CSX, radionuclide 123 I-MIBG uptake is completely absent, although the liver and lung are clearly visible. Th is implicates signifi cant abnormality in sympathetic heart innervation in patients with non-CAD
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. Involvement of eff erent (nociceptive) fi bers is established directly with electrostimulation of the right heart or pharmacologically with dobutamine or adenosine delivered locally as intracardial infusion 31 .
Integrated ischemic and non-ischemic hypothesis
It is currently presumed that the pathophysiological relationship between ischemic and non-ischemic hypothesis exists. Microvascular dysfunction and repeated subclinical episodes of ischemia could lead to structural changes in heart innervation through fi brosis or prolonged mild infl ammation. Th is is presented as an enhanced pain perception to harmless local stimuli (eff erent innervation) or as a decreased uptake of MIBG in sympathetic heart fi bers, which implicates involvement of aff erent fi bers 32 .
Traditional risk factors such as hypertension, hypercholesterolemia and diabetes have a signifi cant role in the development of microvascular dysfunction through endothelial dependent vasodilatation (endothelial dysfunction) and are part of ischemic hypothesis 33 . Insulin resistance and glucose intolerance are also
Fig. 1. Risk factors for development of non-CAD. Th ere is a relationship between ischemic (endothelial and non-endothelial dependent theory) and non-ischemic (neural and habitual theory) risk factors. Repeated episodes of micro ischemia due to microvascular coronary dysfunction could lead to neural disorder aff ecting adrenergic or nociceptive fi bers through fi brosis and mild prolonged infl ammation. Habitual and neural theory could also be connected.
associated with endothelial dysfunction 34 . Th e lack of estrogen in females and hysterectomy are part of the non-ischemic hypothesis based on analgesic properties of estrogen 35 , while mild infl ammation with increased concentration of C-reactive protein and interleukin-1 receptor antagonists is a possible risk factor in nonischemic and ischemic hypothesis causing structural changes of neural fi bers 36 ( Fig. 1) .
Diagnosis of Nonobstructive Coronary Artery Disease
Diagnosis of non-CAD is based on clinical presentation and diagnostic procedures. Clinical presentation of angina can be more or less typical. Diagnostic tests in non-CAD can be invasive and noninvasive (Table 1) . and pulse pressure product during stress needed to cause ST changes in patients with non-CAD 39 . Th erefore, patients with positive stress test are candidates for further invasive diagnostic work-up to confi rm or exclude obstructive changes of coronary arteries. Usually, direct catheterization of arteries (coronarography) is performed, although there are other noninvasive methods such as multi-slice computerized tomography (MSCT) 6 . Some authors suggest acetylcholine or ergonovine test (intracoronary or intravenously) in patients with normal coronarography to exclude spasm of major arteries. Unfortunately, this procedure is highly risky due to the possibility of strong vasospasm and hypotension, thus it is not part of routine clinical work-up 6 . After exclusion of all non-cardiac causes, diagnosis of CAD is based on clinical presentation of chest pain and diagnostic procedures. First procedure is noninvasive test of physical activity (ergometry, or rarely myocardial stress scintigraphy). In patients with positive stress test, coronarography is performed to defi nitely confi rm or exclude obstructive stenosis (≥50%) of epicardial arteries. Spasm of major arteries can be diagnosed with ergonovine or acetylcholine test but due to the considerable risk it is not part of routine clinical work-up 37 . Routine clinical work-up ends at this point. Additional tests for more accurate diagnosis of non-CAD are used only for research purposes 6 . In patients with suspected ischemic etiology (microvascular dysfunction), some pharmacological tests can be performed to confi rm altered vasodilatation or enhanced vasoconstriction. Th e most commonly performed tests are acetylcholine test or electrostimulation to establish endothelial dependent dysfunction and adenosine, pyridamole or papaverine tests to establish non-endothelial dependent dysfunction. Vasoconstriction can be diagnosed with ergonovine test or cold pressure test 23 . After implementation of one of these tests, establishing induced ischemia in the microvasculature area (<500 μm) is necessary 8 . Since small blood vessels cannot be displayed on coronarography, ischemia is indirectly visualized with invasive methods such as the test of coronary fl ow reserve (CFR) or with noninvasive methods such as myocardial scintigraphy, MR or PET 19, 20 . To confi rm non-ischemic origin of the disorder (altered pain perception), MIBG scintigraphy of sym- It is very important to emphasize that non-CAD is diagnosed by exclusion 6 . Exclusion of all other noncardiac causes of angina such as musculoskeletal pain, gastrointestinal disorders, pulmonary causes and various psychiatric disorders is necessary. In patients with probable angina, noninvasive diagnostic tests are performed trying to confi rm ischemia through signifi cant ST-T changes (based on established standardized diagnostic criteria) mostly during exertion. Th e basic test of physical activity is ergometry or exercise myocardial perfusion scintigraphy 37 . Currently, there are no defi ned criteria for diff erentiating obstructive from nonobstructive disease in patients with positive stress test 38 . However, some authors suggest several criteria such as increased pressure pathetic heart innervation for visualizing aff erent dysfunction and direct heart stimulation with dobutamine or electrostimulator for demonstrating eff erent dysfunction can be performed 25 . Additional tests are also available such as insuffi ciently standardized psychological tests for establishing habitual component of disorder, as well as absence of adaptation to repeated pain stimuli 27 . All additional diagnostic tests are summarized in Table 2 .
Prognosis of Nonobstructive Coronary Artery Disease and Prevalence of Major Cardiovascular Outcomes
Unlike former opinions, current studies have verifi ed that patients with non-CAD have an increased risk of cardiac mortality 11, 40, 41 . Prognosis of non-CAD is not benign considering 2% risk of cardiac death or myocardial infarction within 30 days of disease manifestation 11 . Several studies demonstrated that advanced coronary atheroma could be present despite normal or almost normal coronary arteries 42 , thus increasing the risk of adverse acute events 43 . Th e Women's Ischemia Syndrome Evaluation (WISE) trial, which included women with non-CAD, demonstrated that diff erent symptom profi les were associated with diff erent longterm outcomes 44 . An increase in adverse cardiac events was observed in patients with non-CAD. Th ese fi ndings suggest that normal or almost normal coronary arteries on coronarography do not imply benign prognosis 44 . Furthermore, classic defi nition of coronary disease symptoms encompasses retrosternal chest pain or discomfort (which can irradiate into the neck, arm, jaw and back), with pain quality described as dull, sharp, crushing or burning, lasting for 2-20 minutes and worsened with physical activity, while alleviated with rest or nitroglycerin 45 . On the other hand, the majority of patients (around 70%) in the study performed by Johnson et al. 44 presented with atypical symptoms regardless of verifi ed nonobstructive or obstructive coronary disease on coronarography. As a consequence of this symptom variability, patients with atypical presentation and an increased risk of adverse cardiac events can be easily overlooked. Previous studies performed in patients with angina and normal coronarography in the 1960s did not demonstrate an increased prevalence of adverse clinical events, or increased mortality 46 . Th ose studies were performed in a small number of patients with short follow-up; therefore, the increased risk in those patients was not determined 47 . Th e WISE trial was the fi rst study that demonstrated completely opposite results in females with CSX. Th ose patients had a three-fold higher prevalence of adverse cardiovascular events (including heart failure and stroke) compared to healthy controls during the 5-year follow-up (2.4% vs. 7.9%; p=0.002) 44 . Th ese results were confi rmed by the British Columbia registry, which established a 4 times higher probability of hospital readmission in females with angina and nonobstructive changes on coronarography presenting as acute coronary syndrome compared to males during early follow-up 48 . However, the WISE trial was not successful in establishing statistically higher prevalence of myocardial infarction or cardiac death compared to healthy population, despite numerical diff erences. Nevertheless, the total mortality rate was signifi cantly higher compared to the control group (2.1% vs. 3.0%; p=0.04) 44 . Th is observation is extremely important since a high mortality rate was established for the fi rst time in women with non-CAD. It is considered that prognosis in females with non-CAD depends on microvascular dysfunction 49 . Several studies demonstrated that patients with CSX and established microvascular dysfunction had a higher probability of developing CAD in the future and higher prevalence of adverse cardiovascular events 50 . Moreover, investigators in the WISE trial additionally stratifi ed patients with nonobstructive disease in two groups. First group consisted of patients with confi rmed ischemia using MR spectroscopy (indirect proof of microvascular dysfunction), whereas in the second group of patients diagnosis of ischemia with that method was not possible. In the group of patients with confi rmed ischemia and microvascular dysfunction, a higher prevalence of adverse cardiovascular events was observed even when considering all traditional risk factors 44 . Th e WISE trial included only women, thus it is still unclear whether the same observations apply to male population.
In 2012, Jespersen et al. 51 . published results from the Copenhagen City Heart trial including 11,233 patients that underwent coronarography due to the symptoms of stable angina and were compared to healthy individuals without cardiovascular events. Signifi cantly more females (65%) compared to males (32%) had non-CAD among patients with stable coronary disease. Th is is consistent with the observations from the WISE trial that 62% of patients who underwent coronarography due to chest pain had non-CAD. Th e Danish trial was designed as a retrospective cohort study including all patients from eastern Denmark that underwent coronarography due to angina from 1998 to 2009 51 . Th is trial demonstrated that both males and females with anginal symptoms and normal or nonobstructive changes of coronary arteries had an increased risk of adverse cardiovascular events compared to healthy population without ischemic events. Th at specifi c group of patients with normal coronary arteries or nonobstructive changes of coronary arteries had 52% and 85% increased risk of major adverse cardiac events (MACE) including cardiac death, hospitalization due to myocardial infarction and heart failure or stroke, and 29% and 52% had an increased mortality risk regardless of the cause. Th ere was no statistically signifi cant diff erence for MACE or mortality rate between men and women 51 .
Treatment of Nonobstructive Coronary Artery Disease
Treatment of non-CAD presents a great challenge. Unfortunately, therapy is often unsuccessful because symptoms persist at 5-year follow-up in almost 50% of treated women 54 . Th ere are few medications and procedures that are undoubtedly effi cient in CSX treatment. Experiences gathered from large clinical trials are lacking. Most of observations and conclusions are based on smaller and observational studies that included only a few dozens of patients or less. Results of those trials are mostly contradictory or lacking well defi ned control groups for comparison. Th e Eff ects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients with Cardiac Syndrome X (APEX) trial is one of the few clinically controlled pending trials (started in 2008) that is trying to evaluate specifi c drug effi cacy, in this case allopurinol, in treating CSX 55 . However, based on the current knowledge, it is safe to say that beta-blockers and lifestyle changes modifying cardiovascular risk factors have a central role in non-CAD treatment 55 . All therapeutic measures in non-CAD treatment can be divided into medicamentous and non-medicamentous measures that are summarized in Table 3 .
Medicamentous measures
Th ere are numerous small trials demonstrating atenolol effi cacy in CSX treatment [56] [57] [58] . Atenolol decreases pain, improves coronary reserve, and decreases ST depression during exertion test 56 . Th e calcium channel blockers verapamil and amlodipine were not effi cient compared to atenolol, although there are some reports indicating benefi cial eff ect of atenolol and amlodipine combination 56 . Unfortunately, controlled experiences with other beta-blockers are lacking. Nebivolol is the only drug investigated in patients with non-CAD. Nebivolol is a highly selective beta-1-blocker with benefi cial eff ect on endothelial function, which increases bioavailability of the most potent endogenous vasodilator NO 55 . Upon intracoronary infusion, it increases coronary reserve in patients with and without obstructive changes in the epicardial arteries. However, intracoronary application of this drug is not clinically possible, while experiences with oral usage are still lacking.
Investigators generally agree that beta-blockers have benefi cial eff ect, although there is a response variability of 19%-60% 59 . However, based on current research, beta-blockers (especially atenolol) should be the fi rst line treatment in patients with CSX 60 . Although expected, effi cacy of nitrates in CSX treatment is still questionable. In small observational studies, effi cacy was present in only 42% of patients. Moreover, there are some reports indicating decreased tolerance during the test of physical activity in those patients when treated with nitrates 61 . Th erefore, nitrates are recommended exclusively in combination with other effi cient drugs 56 .
Th e xanthine derivatives aminophylline and theophylline are blocking adenosine receptors, thus enabling more favorable redistribution of coronary fl ow and probably blocking adenosine eff ect in pain provocation (intracoronary infusion of adenosine elicits chest pain in patients with CSX) 6, 55 . Intravenous or oral administration of aminophylline during the test of physical activity increases exercise tolerance, diminishes pain perception, and decreases ST changes 62, 63 . Th erefore, these medications can be recommended, especially in patients treated for asthma or chronic obstructive pulmonary disease 55 . In small observational and placebo controlled trials, some angiotensin-converting enzyme (ACE) inhibitors had certain benefi cial eff ect 64 , this referring to cilazapril 65 , enalapril 66 and a combination of ramipril and statin (atorvastatin) 55 . Antagonists of angiotensin receptors (ARB), despite expectations, did not demonstrate any favorable eff ects in a trial investigating irbesartan 67 . For other members of this group, effi cacy was neither investigated nor established.
In several studies, statins showed some effi cacy in treating CSX, probably due to their anti-infl ammatory eff ect. Th e eff ect was present regardless of the plasma lipid profi le baseline values 68, 69 . Furthermore, additional synergic eff ect was established with some ACE inhibitors, especially for atorvastatin and ramipril 6, 55, 68 . Of all other medications utilized in CSX treatment that had certain success, we should mention estrogen in postmenopausal women 55, 70 , L-arginine (precursor -ACE = angiotensin-converting enzyme; COPB = chronic obstructive pulmonary disease; SCS = spinal cord stimulation; TENS = transdermal electric nerve stimulation; EECP = extracorporeal enhanced counter pulsation; ARB = angiotensin II receptor blockers of vasodilator NO) 71, 72 , metformin in patients with glucose intolerance 73 , and imipramine that is used in the treatment of chronic pain 74, 75 . Th e effi cacy of α-antagonists (doxazosin and clonidine) has not yet been established in the treatment of non-CAD symptoms 76 . Th ere are several new drugs with probable therapeutic eff ect in CSX based on their mechanism of action. However, currently there is no strong evidence to confi rm their effi cacy and justify their application. Some of these drugs are bosentan (ET-1 inhibitor), cariporid (Na-H+ exchanger), fasudil (rho-kinase inhibitor) and trimetazidine (metabolic antianginal drug) 55 . Only nicorandil, activator of vascular potassium channels with vasodilatory abilities, is eff ective in the treatment of microvascular coronary disease 77, 78 .
Non-medicamentous measures
Besides the above mentioned pharmacological measures in the treatment of CSX symptoms, there are also non-medicamentous procedures that exhibited favorable eff ect in some patients. Spinal cord stimulation (SCS) with low voltage electric impulses aff ects pain modulation and diminishes pain sensation in patients with angina 79 . Th is method is approved in the treatment of refractory angina in patients with CAD unsuitable for revascularization, and has class IIb recommendation according to the American College of Cardiology/American Heart Association (AHA/ACC) guidelines 80 . Th ere are several reports indicating efficacy of this method in long-term control of symptoms in patients with CSX 79, 81 .
Similar procedure is transdermal electric nerve stimulation (TENS). Th is procedure improves coronary fl ow without altering microvasculature diameter and has benefi cial eff ect in eliminating symptoms [82] [83] [84] . Extracorporeal enhanced counter pulsation (EECP) consists of periodical infl ating and defl ating pressure cuff s on lower extremities that proved efficient in recovering endothelial function and in some small studies led to diminishing anginal symptoms 85 . Lifestyle modifi cations and aff ecting cardiovascular risk factors are basic recommendations for patients with non-CAD 55 . Physical exercise improves coronary reserve and exercise tolerance, and diminishes symptoms in both CAD and non-CAD 86 . Additional improvement of exercise tolerance, quality of life, and benefi cial eff ect on anginal symptoms can be achieved through rehabilitation 87, 88 . Recommendations are weight reduction 89 , smoking cessation 90 and low fat or Mediterranean diet 91 , which improves endothelial dysfunction 55 .
New Classifi cation of Nonobstructive Coronary Artery Disease Suggested
We propose here a new classifi cation of non-CAD, separating the whole syndrome in type I (ischemic disease) and type II (non-ischemic disease), based on which clinical syndrome predominates. Each of these is further divided based on the existing mechanism and is marked by letters A, B or C, as shown in Table 4 .
Disorder 1A represents endothelial dependent reduced vasodilatation, which clinically corresponds to Non-ischemic mechanisms may also be divided into three basic groups, and are marked by letters A, B and C: 2A is a neurogenic aff erent mechanism, which clinically represents adrenergic disorder of heart innervation; 2B is neurogenic eff erent mechanism that clinically represents nociceptive disorder; and 2C is habitual mechanism that represents behavioral disorder.
In clinical practice, the same patient may have more of less combined induced mechanisms. However, there is always one predominant mechanism in clinical presentation of non-CAD, and the disorder can be classifi ed by that predominant mechanism.
Certainly, microvascular dysfunction plays a signifi cant role in the development of non-CAD, but other mechanisms should not remain unattended. Th ese pathophysiological mechanisms are well defi ned and lead to anginal symptoms, and aff ect major coronary arteries, not the microvasculature. Th is especially refers to vasospastic, Prinzmetal's angina, and phenomenon of myocardial bridging. Both aff ect major coronary arteries and should be placed among the mechanisms of non-CAD.
With this new classifi cation, the aim is to include all the known pathophysiological mechanisms and align classifi cation to current diagnostic testing, thus hopefully contributing to better understanding, timely diagnosis and comprehensive management of non-CAD. 16 
